Business Context and Reporting Period
This Form 8-K Current Report is filed by Allogene Therapeutics, Inc. (Nasdaq: ALLO) for the reporting period of April 13, 2026. The filing addresses Item 8.01 (Other Events) regarding a proposed capital raise.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding equity issuance rather than financial performance results.
Material Changes
- Proposed Public Offering: On April 13, 2026, the Company announced the commencement of a proposed underwritten public offering of its common stock.
- Suspension of At-the-Market Sales: In connection with the proposed offering, the Company has suspended the sale of common stock under its existing Sales Agreement with TD Securities (U.S.A.) LLC (f/k/a Cowen and Company, LLC), dated November 5, 2019 (as amended).
- Prospectus Requirement: No further sales under the Sales Agreement will occur until a new prospectus or prospectus supplement is filed with the SEC.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard legal disclaimer that this report does not constitute an offer to sell securities. The primary contingency noted is the requirement to file a new prospectus before resuming sales under the suspended Sales Agreement.
Investor Verification Checklist
- Verify the size and pricing of the proposed underwritten public offering in subsequent filings (e.g., Form S-1 or prospectus supplement).
- Monitor the status of the suspended Sales Agreement with TD Securities to determine when it may be reinstated.
- Review the Company's cash position in the most recent 10-Q or 10-K to assess the necessity and impact of this capital raise.
- Confirm the final terms of the offering once the underwriting agreement is executed.